A Case of Von Hippel–Lindau Disease with Bilateral Pheochromocytoma and Ectopic Hypersecretion of Intact Parathyroid Hormone in an Adolescent Girl

Rym Belaid, Ibtissem Oueslati, Melika Chihaoui, Meriem Yazidi, Wafa Grira, and Fatma Chaker

Department of Endocrinology, La Rabta University Hospital, Faculty of Medicine, University of Tunis El Manar, Tunis, Tunisia

Correspondence should be addressed to Ibtissem Oueslati; ouesibtissem@gmail.com

Received 10 June 2020; Revised 27 July 2020; Accepted 30 July 2020; Published 7 August 2020

Copyright © 2020 Rym Belaid et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Von Hippel–Lindau disease is an autosomal dominant inherited syndrome predisposing to a variety of highly vascularised tumors in different organs. Although bilateral pheochromocytoma was reported in patients with von Hippel–Lindau disease, the coexistence of primary hyperparathyroidism is not a common condition. We report an observation of a primary hyperparathyroidism secondary to an ectopic secretion of intact parathyroid hormone in a 17-year-old girl with von Hippel–Lindau disease and bilateral pheochromocytoma. She presented with a newly diagnosed diabetes mellitus and a severe arterial hypertension. Blood tests disclosed hypercalcemia with increased intact PTH level. Cervical ultrasound and sestamibi scintigraphy were normal. Twenty-four-hour urinary normetanephrine level was highly elevated pointing to a catecholamine-secreting tumor. Abdominal computed tomography showed bilateral adrenal masses. MIBG scintigraphy exhibited a high accumulation of the tracer in both adrenal tumors. Genetic testing revealed a mutation of the VHL gene. The patient underwent a bilateral adrenalectomy. The postoperative outcome was marked by normalization of blood pressure, blood glucose, calcium, and PTH levels. In our case, the elevation of intact PTH and its spontaneous normalization after surgical treatment of pheochromocytomas confirms its ectopic secretion.

1. Introduction

Pheochromocytomas are uncommon neuroendocrine tumors that arise from chromaffin cells of the adrenal medulla and produce excessive amounts of catecholamines: epinephrine, norepinephrine, and dopamine [1]. Although most pheochromocytomas are sporadic, more than 25% are associated with an inherited mutation, and this frequency can be as high as 55%, if diagnosed before 18 years of age [2]. In childhood, pheochromocytomas are mostly due to genetic causes including von Hippel–Lindau (VHL) disease, multiple endocrine neoplasia type 2 (MEN2), hereditary pheochromocytoma paraganglioma syndrome, and rarely neurofibromatosis type 1 [3]. Compared to adults, VHL disease is reported to be the most frequent genetic disorder causing pheochromocytomas in children [4]. While bilateral pheochromocytomas were reported in patients with VHL disease, the coexistence of primary hyperparathyroidism is not a common condition [5].

Herein, we report a case of a VHL disease with bilateral pheochromocytoma and an ectopic secretion of intact parathyroid hormone in an adolescent girl.

2. Presentation of Case

A 17-year-old girl was referred to our department for the investigation of a newly diagnosed diabetes mellitus and a severe arterial hypertension. She was the first child of consanguineous parents. Her past medical history was unremarkable. Her family history was notable for type 2 diabetes and dyslipidemia but no history of pheochromocytoma, paraganglioma, unexplained sudden death, or
condition that may lead to thinking about VHL disease was reported.

As symptoms, the patient complained of headaches, palpitations, diaphoresis, and hot flashes since one month. She reported also asthenia and body weight loss of five kilograms in two weeks.

On examination, she had a body weight of 50 kg, a body height of 154 cm, a body mass index of 21.1 kg/m², a blood pressure of 200/100 mmHg without orthostatic hypotension, a regular pulse of 120 bpm, and a large abdominal café-au-lait spot (Figure 1). Thyroid, abdominal, and neurological examinations were normal.

Twenty-four-hour blood pressure monitoring confirmed the diagnosis of hypertension and the presence of peaks of 230/110 mmHg. Electrocardiogram showed a sinus tachycardia. Capillary glucose level was 2.68 g/l without ketosis.

Fundoscopy showed grade 3 hypertensive retinopathy without any other abnormalities.

The results of biological investigations are shown in Table 1.

The diagnosis of clinically suspected pheochromocytoma was confirmed by the dosage of urinary methoxylated derivatives at 5 times the upper limit of normal. In addition, the diagnosis of diabetes mellitus, dyslipidemia, and primary hyperparathyroidism were made.

The abdominal computed tomography (CT) showed two adrenal masses: the first on the right measuring $35 \times 55 \times 70$ mm with a spontaneous density of 30 HU heterogeneously enhanced in the arterial time showing areas of necrosis with an absolute washout of 40%, the second on the left measuring $24 \times 27$ mm with the same characteristics as the first one (Figure 2). There were neither other localizations nor lymph nodes. Metaiodobenzylguanidine (MIBG) scintigraphy exhibited a high accumulation of the tracer in both adrenal tumors without any other localization. Cervical ultrasound and 99mTc-sestamibi scintigraphy were normal. Cardiac ultrasound was normal.

The diagnosis of multiple endocrine neoplasia type 2a was highly suspected, and the patient underwent a molecular investigation. DNA analysis did not find a RET proto-oncogene mutation. However, it showed a missense mutation c.191G>C (p.Arg64Pro) in exon 1 of the VHL gene on chromosome 3. The diagnosis of bilateral pheochromocytoma in the setting of VHL disease was established. Abdominal CT scan and craniospinal magnetic resonance imaging with contrast did not show any cysts or other tumors.

The patient was treated with an alpha blocker, prazosine, a calcium channel blocker, a beta blocker, and insulin at a daily dose of 1.4 units/kg. She underwent a bilateral adrenalectomy in two steps. The pathological examination confirmed bilateral adrenal pheochromocytomas. Replacement therapy with hydrocortisone was initiated after surgery.

The postoperative outcome was determined by the spontaneous normalization of blood pressure, blood glucose, calcium, and PTH levels. The patient remained asymptomatic with no evidence of local recurrence or distant metastasis during the 12 months of follow-up. The family screening for VHL has not been performed yet.

3. Discussion

VHL disease is a dominantly inherited familial cancer syndrome caused by a germline mutation in the VHL tumor suppressor gene and predisposing to a variety of benign and malignant neoplasms most frequently retinal, central nervous system and spinal hemangioblastomas, renal cell carcinoma (RCC), pheochromocytoma, and pancreatic tumors [6, 7]. While central nervous system and retinal hemangioblastomas are the earliest expressions of the VHL syndrome, pheochromocytoma may be the first manifestation of the disease especially in children and adolescents as it was the case of our patient [6–8]. The frequency of pheochromocytoma in VHL syndrome is about 10 to 20% [6].

Families with VHL disease have been divided into two subtypes: VHL type 1 and VHL type 2, based on the likelihood of developing a pheochromocytoma. The presence of pheochromocytoma defines types 2 VHL disease. This latter is subdivided based on the risk of developing RCC. Type 2A and 2B families have a low and high incidence of RCC, respectively, whereas VHL type 2C kinds are characterized by the development of pheochromocytoma without any other manifestations of the disease [7]. However, late onset of other attacks is possible, and a follow-up, even spaced, is required [9].

Genotype-phenotype correlations have been documented for this disorder, and specific mutations are associated with the appearance of tumors in certain organs. While most type 2 families were reported to be more likely carrying a missense mutation in the VHL gene, most type 1 families are affected by truncating or deletion mutations [10]. In our case, the presence of pheochromocytomas and the missense mutation in VHL gene suggested type 2 VHL disease. Moreover, the mutation found in our patient, p.Arg64Pro, has been described in patients with isolated pheochromocytoma, associated with RCC or with pancreatic neuroendocrine tumor [11–13]. However, our patient did not present any sign of RCC or pancreatic neuroendocrine tumor during the 12 months of follow-up. This evaluation may be early in our case as RCC and pancreatic neuroendocrine tumors in patients with VHL disease generally appear at more advanced ages (around 25–35 years) [7].

Pheochromocytoma in VHL disease tends to be seen at a younger age and is more frequently multifocal, as in our patient and may be extra-adrenal [14, 15]. In most published cases, the mean age at presentation was about 30 years, but very young cases have been described, the youngest before 5 years [7, 10]. In addition, VHL-associated pheochromocytomas are less likely to be associated with symptoms or biochemical evidence of catecholamines production compared with those occurring in patients without VHL [16, 17]. In a report of the National Institute of Health about 64 patients with VHL disease and pheochromocytomas, a total of 106 tumors were identified. Of these, 12% originated outside the adrenal gland, and 35% of the patients were asymptomatic, without hypertension or evidence of
increased catecholamines production [15]. This was not the case of our patient who had sustained severe hypertension associated with the classic symptoms of pheochromocytoma (palpitation, sweating, and hot flashes), hypokalemia, and a secondary diabetes mellitus. In our case, as reported in the literature [16, 17], a remarkable remission of diabetes

| Table 1: Biological parameters before and after surgery. |
|--------------------------------------------------------|
| **Before surgery** | **After surgery** | **Reference ranges** |
|---------------------|------------------|---------------------|
| Fasting glucose level (mmol/l) | 16.39 | 4.78 | 4.12–5.55 |
| Glycated hemoglobin (%) | 10.12 | 5.91 | ≤5.6 |
| Total cholesterol (mmol/l) | 11.83 | 5.23 | 3.1–5.18 |
| Triglycerides (mmol/l) | 2.43 | 1.21 | 0.57–1.71 |
| Natremia (mmol/l) | 135 | 140 | 135–145 |
| Kalemia (mmol/l) | 3.3 | 4 | 3.6–5 |
| Creatinine (mg/L) | 6 | 6 | 4–13 |
| Calcium (mg/L) | 111.2 | 98 | 88–105 |
| Phosphate (mg/L) | 44 | 36 | 27–45 |
| Albumin (g/l) | 47.22 | — | 35–52 |
| Intact PTH* (μg/L) | 182 | 54 | 11–62 |
| TSH (mUI/L) | 0.625 | — | 0.12–3.4 |
| FT4 (ng/dl) | 1.31 | — | 0.71–1.85 |
| Calcitonin (ng/L) | 2.70 | — | <10.00 |
| 24h-urine NMN (μg/24) | 3150 | 570 | 30–600 |
| 24h-urine MN (μg/24) | 40.2 | 12 | 20–345 |
| 24h-urine sodium (mmol/24h) | 88.5 | — | — |
| 24h-urine potassium (mmol/24h) | 60 | — | — |
| 24h-urine calcium (mg/24h) | 200 | — | — |
| 24h-proteinuria (g/24) | 0.3 | — | <0.3 |

*The intact PTH dosage was made using 3rd generation chemiluminescence immunoassay.

Figure 1: A large abdominal café-au-lait spot.

Figure 2: Abdominal computed tomography showing the two adrenal masses (two white arrows).
mellitus and an improvement of lipid profile were noticed after tumor removal confirming the secondary character of these two metabolic disorders. In fact, catecholamine excess affects insulin secretion, decreased glucose uptake in the peripheral tissues, and increased insulin resistance leading to impaired fasting glucose or overt diabetes mellitus [18]. Moreover, the increase in catecholamine production may be responsible for decreased inhibition of lipolysis by insulin and decreased activity of lecithin-cholesterol acyltransferase, an enzyme which breaks down free cholesterol [1].

The risk of malignancy is low. Less than 5% of all pheochromocytomas in VHL disease are malignant [7]. In our case, neither distant metastasis nor lymph nodes were found, but a long term follow-up should be carried out.

Measurement of plasma or urinary metanephrines and normetanephrines is the gold standard in diagnosing pheochromocytoma and can also provide important diagnostic information [1]. In fact, in a study carried out by Eisenhofer et al. [14], comparing the clinical and biochemical characteristics of pheochromocytomas in multiple endocrine neoplasia type 2 versus the VHL syndrome and including 19 and 30 patients with these disorders, respectively, VHL patients almost exclusively produced normetanephrines. So, a high normetanephrines-to-metanephrines ratio is expected in patients with VHL disease, as was found in our patient. Furthermore, in comparison with MEN2 tumors, VHL tumors had lower total tissue contents of catecholamines and expression of tyrosine hydroxylase (TH), the rate-limiting enzyme in catecholamine synthesis. They also had much lower expression of phenylethanolamine N-methyltransferase (PNMT, the enzyme that converts norepinephrine to epinephrine) and tissue stores of epinephrine [14]. Regarding the histopathological features, VHL-associated pheochromocytomas are characterized by a thick vascular tumor capsule and are in contrast to MEN 2 not associated with adrenal medullary hyperplasia [19].

While bilateral pheochromocytomas were reported in patients with VHL disease, the coexistence of primary hyperparathyroidism as in our case is not a common condition [5]. Hypercalcemia associated with pheochromocytoma has been documented and is thought to be caused by several mechanisms. First, elevated catecholamines can activate the PTH receptor resulting in catecholamine-induced osteoclastic bone resorption, but in contrast to our case, the PTH level is not elevated [20]. Secondly, hypercalcemia can be due to the production of PTH-related peptide (PTH-rp) by the tumor which was doubtless not the case in our patient as the level of intact PTH was elevated [21]. Furthermore, intact PTH in our case was quantified using a 3rd generation chemiluminescence immunoassay which does not recognize PTH-rp.

Third, parathyroid adenoma can be a part of multiple endocrine neoplasia that was, however, rarely reported in VHL disease [5]. The negativity of the topographic investigations and the spontaneous normalization of intact PTH after surgical treatment are against this hypothesis. Finally, although the exact physiopathological mechanism is not clear, the fact that both serum calcium and PTH levels were elevated before surgery and became normal after the removal of the pheochromocytoma strongly suggests that the tumor itself was secreting PTH or a substance that stimulates excessive PTH secretion by the parathyroid glands. Only few cases of ectopic hormonal secretion by pheochromocytoma such as adrenocorticotrophic hormone (ACTH), calcitonin, parathyroid hormone (PTH), vasoactive intestinal peptide (VIP), and growth hormone-releasing hormone (GHRH) were reported [22, 23]. Unfortunately, immunohistochemistry assay for PTH in the tumor tissue was not available to clarify this question in our case.

4. Conclusion

This report highlights the rare case of ectopic intact PTH secretion by a bilateral pheochromocytoma in an adolescent girl with VHL disease. We consider that controlling calcium and PTH after adrenalectomy is useful if the topographic assessment of primary hyperparathyroidism is negative.

To the best of our knowledge, our patient is the second youngest reported childhood VHL case in the literature, presenting with a bilateral pheochromocytoma secreting ectopic intact PTH. Genetic testing and a meticulous follow-up are necessary for the diagnosis of the associated comorbidities in VHL disease.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Acknowledgments

The authors thank Professor Anne Barlier (Laboratory of Molecular Biology, Hospital La Conception, Marseille, France) for her help in molecular study.

References

[1] J. W. M. Lenders, Q.-Y. Duh, G. Eisenhofer et al., “Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline,” The Journal of Clinical Endocrinology & Metabolism, vol. 99, no. 6, pp. 1915–1942, 2014.
[2] E. Sbardella, T. Cranston, A. M. Isidori et al., “Routine genetic screening with a multi-gene panel in patients with pheochromocytoma,” Endocrine, vol. 59, no. 1, pp. 175–182, 2018.
[3] S. G. Waguespack, T. Rich, E. Grubbs et al., “A current review of the etiology, diagnosis, and treatment of pediatric pheochromocytoma and paraganglioma,” The Journal of Clinical Endocrinology & Metabolism, vol. 95, no. 5, pp. 2023–2037, 2010.
[4] M. Barontini, G. Levin, and G. Sanso, “Characteristics of pheochromocytoma in a 4- to 20-year-old population,” Annals of the New York Academy of Sciences, vol. 1073, no. 1, pp. 30–37, 2006.
[5] T. Arao, Y. Okada, T. Tanikawa et al., “A case of von Hippel-Lindau disease with bilateral pheochromocytoma, renal cell
carcinoma, pelvic tumor, spinal hemangioblastoma and primary hyperparathyroidism,” *Endocrine Journal*, vol. 49, no. 2, pp. 181–188, 2002.

[6] A. N. A. V. D. Horst-Schrivers, W. J. Sluiter, R. C. Kruizinga et al., “The incidence of consecutive manifestations in Von Hippel-Lindau disease,” *Familial Cancer*, vol. 18, no. 3, pp. 369–376, 2019.

[7] R. R. Lonser, G. M. Glenn, M. Walther et al., “von Hippel-Lindau disease,” *The Lancet*, vol. 361, no. 9374, pp. 2059–2067, 2003.

[8] A. D. Çakır, H. Turan, A. Aykut, A. Durmaz, O. Ercan, and O. Eviyaoğlu, “Two childhood pheochromocytoma cases due to von Hippel-Lindau disease, one associated with pancreatic neuroendocrine tumor: a very rare manifestation,” *Journal of Clinical Research in Pediatric Endocrinology*, vol. 10, no. 2, pp. 179–182, 2018.

[9] S. P. Rednam, A. Erež, H. Druker et al., “Von hippel-lindau and hereditary pheochromocytoma/paraganglioma syndromes: clinical features, genetics, and surveillance recommendations in childhood,” *Clinical Cancer Research*, vol. 23, no. 12, pp. e68–e75, 2017.

[10] G. F. C. Fagundes, J. Petenuci, D. M. Lourenço et al., “New insights into pheochromocytoma surveillance of young patients with VHL missense mutations,” *Journal of the Endocrine Society*, vol. 3, no. 9, pp. 1682–1692, 2019.

[11] F. Hes, R. V. D. Luitj, A. Janssen et al., “Frequency of Von Hippel-Lindau germline mutations in classic and non-classic Von Hippel-Lindau disease identified by DNA sequencing, Southern blot analysis and multiplex ligation-dependent probe amplification,” *Clinical Genetics*, vol. 72, no. 2, pp. 122–129, 2007.

[12] T. Krauss, A. M. Ferrara, T. P. Links et al., “Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors,” *Endocrine-Related Cancer*, vol. 25, no. 9, pp. 783–793, 2018.

[13] E. Wittström, M. Nordling, and S. Andråsson, “Genotype-phenotype correlations, and retinal function and structure in von Hippel-Lindau disease,” *Ophthalmic Genetics*, vol. 35, no. 2, pp. 91–106, 2014.

[14] G. Eisenhofer, M. M. Walther, T.-T. Huynh et al., “Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 86, no. 5, pp. 1999–2008, 2001.

[15] M. M. Walther, R. Reiter, H. R. Keiser et al., “Clinical and genetic characterization of pheochromocytoma in von Hippel-Lindau families: comparison with sporadic pheochromocytoma gives insight into natural history of pheochromocytoma,” *Journal of Urology*, vol. 162, no. 3, pp. 659–664, 1999.

[16] J. Cha, M. Khurram, L. Gellert, P. Epstein, N. Baregian, and C. Hendrickson, “Case of reversible diabetes mellitus in the setting of benign Pheochromocytoma,” *Journal of Clinical and Translational Endocrinology: Case Reports*, vol. 10, pp. 1–3, 2018.

[17] M. L. Good, P. Malekzadeh, S. M. Ruff et al., “Surgical resection of pheochromocytomas and paragangliomias is associated with lower cholesterol levels,” *World Journal of Surgery*, vol. 44, no. 2, pp. 552–560, 2020.

[18] B. Mesmar, S. Poola-Kella, and R. Malek, “The physiology behind diabetes mellitus in patients with pheochromocytoma: a review of the literature,” *Endocrine Practice*, vol. 23, no. 8, pp. 999–1005, 2017.

[19] O. Mete, A. S. Tischler, R. D. Krijger et al., “Protocol for the examination of specimens from patients with pheochromocytomas and extra-adrenal paragangliomas,” *Archives of Pathology & Laboratory Medicine*, vol. 138, no. 2, pp. 182–188, 2014.

[20] N. O. Atuk, T. McDonald, T. Wood et al., “Familial Pheochromocytoma, Hypercalcemia, and von Hippel-Lindau Disease: a ten year study of a large family,” *Medicine*, vol. 58, no. 3, pp. 209–218, 1979.

[21] K. Takeda, N. Hara, M. Kawaguchi, T. Nishiyama, and K. Takahashi, “Parathyroid hormone-related peptide-producing non-familial pheochromocytoma in a child,” *International Journal of Urology*, vol. 17, no. 7, pp. 673–676, 2010.

[22] J. Kirkby-Bott, L. Brunaud, M. Mathonet et al., “Ectopic hormone-secreting pheochromocytoma: a francophone observational study,” *World Journal of Surgery*, vol. 36, no. 6, pp. 1382–1388, 2012.

[23] L. V. Neto, G. F. Taboada, L. L. Corrêa et al., “Acromegaly secondary to growth hormone-releasing hormone secreted by an incidentally discovered pheochromocytoma,” *Endocrine Pathology*, vol. 18, no. 1, pp. 46–52, 2007.